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FK 506 reverses acute graft-versus-host 
disease after allogeneic bone marrow 
transplantation in rats 
Peter M. Markus, MD, Xin Cai, MD, Wei Ming, MD, Anthony J. Demetris, MD, 
John J. Fung, MD, PhD, and Thomas E. Starzl, MD, PhD, Pittsburgh, Pa. 
Severe graft-versus-host disease was induced by transplantation of AGI rat bone 
marrow and spleen cells into irradiated Lewis rat recipients. Treatment with FK 506 
or cyclosporine A (GsA) was started after clinical and histologic evidence of acute 
eVHD was present. A 74-day course of FK 506 at 1.0 mg/kg/day could rescue 100% 
of the animals suffering from eVHD. In contrast only one half of the animals treated 
with GsA at a high dose of 25 mg/kg/day recovered. After cessation of 
immunosuppressive therapy, FK 506-treated animals displayed a marked prolonged 
disease-free interval as compared to GsA-treated bone marrow recipients. Recurrence of 
the disease in these animals could be prevented when FK 506 treatment was continued 
after the induction period with a low maintenance dose of O. 7 mg/kg/day every other 
day. (SURGERY 7997;110:357-64.) 
From the Department of Surgery, Division of Transplantation Surgery, and the Department of 
Pathology, the University of PittsbUlgh, School of Medicine, and the Veterans Administration 
Medical Center, Pittsburgh, Pa. 
TRANSPLANTATION OF ALLOGENEIC BONE marrow 
(BM) has become an accepted treatment for a variety of 
malignant and nonmalignant disorders. 1 However, acute 
graft-versus-host disease (GVHD) develops in about 
40% to 80% of these patients despite prophylactic 
immunosuppression.2 Treatment of acute GVHD, once 
established, has been attempted with a variety of regi-
mens including cyclosporine A (CsA),3 methylpred-
nisolone,4 antithymocyte globulin,s monoclonal anti-
bodies against T cells,6 and combinations of these 
agents. Despite these advances in immunosuppression, 
GVHD remains the major cause of morbidity and death 
during the first months after allogeneic bone marrow 
transplantation (BMTx).7 
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Because of the limited success of current therapy, 
more potent immunosuppressive agents are required to 
reverse established GVHD. The new immunosuppres-
sive agent FK 506 has been shown to suppress immune 
responsesB and to prolong graft survival in rats,9,10 
dogs, 11 baboons,12 and more recently in humans. 13-15 
Although its mode of action is similar to CsA, in vitro 
and in vivo assay experiments have shown FK 506 to be 
far more potent than CsA.8- 16 Therefore we evaluated 
the use of FK 506 for the treatment of established acute 
GVHD in a rat model. 
MATERIAL AND METHODS 
Animals. Male Lewis (RT11) and male ACI (RT1a) 
rats weighing 200 to 225 grams were purchased from 
Harlan Sprague-Dawley, Indianapolis, Ind., and main-
tained in a laminar flow caging system (Thoren Caging 
Systems, Hazelton, Pa.). 
BM and spleen cell transplantation. BM and 
spleens from ACI donors were harvested, and a total of 
60 X 106 BM cells and 30 X 106 spleen cells were 
transplanted to Lewis recipients through the penile vein 
2 hours after 1000 rad total-body irradiation, delivered 
from l37Cs source. Animals received penicillin/strepto-
mycin/gentamicin on day 0 followed by gentamicin in-
jections on days 1 and 2. 
Immunosuppression. FK 506 was provided by Fu-
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Table I. Grading of GVHD 
Clinical assessment* 
Histopathologic assessment 
Severity Skin 
Surgery 
August 1991 
Erythematous ear 
Weight loss 
Hyperkeratosis of the footpad 
Unkempt appearance 
Dermatitis 
+ Vacuolar degeneration and necrosis of the basal layer of epidermis and 
mild lymphocyte infiltration of the epidermis 
++ 
+++ 
Eosinophilic necrosis, spongiosis, dyskeratosis, and above 
Massive lymphocyte infiltration of the epidermis and 
Diarrhea focal microscopic epidermal-dermal separation 
·Three or more signs ronsidered positive for GVHD. 
Table II. Treatment groups 
Group n Reconstitution Immunosuppression Dose (mg/kg) Days of therapy 
6 None 
2 10 ACI 
3 12 ACI 
4 9 ACI 
5 8 LEW 
6 8 ACI 
7 6 ACI 
8 8 ACI 
jisawa Pharmaceutical Company, Osaka, Japan. The 
powder with carrier solvent, HCO-60 and D-mannitol, 
was diluted in normal saline. CsA obtained from San-
doz Pharmaceuticals, Hanover, N.j., was dissolved at 
15 mg or 25 mg in 1 ml of intralipid for intramuscular 
injections. Both agents were prepared shortly before 
daily intramuscular administration. 
Assessment of GVHD. Rats were weighed every 3 
days and assessed daily for clinical signs of GVHD. 
Histologic and clinical criteria of GVHD are described 
in Table 1,17-19 Weekly ear biopsies were taken from 
three to four animals of each group. The grading of his-
topathologic findings was assessed in a blind manner. 
Assessment of chimerism. Four weeks after BMTx, 
four rats from each group were randomly chosen and 
assessed for the presence of ACI donor-type lympho-
cytes in the peripheral blood with three different mon-
oclonal antibodies for detection of lymphocyte major 
histocompatibility complex class I antigens20 (Fig. 1). 
Monoclonal antibody (MAb) 163 (IgG 2b) is specific for 
the RT1.Al antigen on Lewis cells, although MAb 211 
(IgG 2b) is specific for the R T1.A a antigen on ACI cells. 
MAb 42-RT1.An was used as an irrelevant control. 
MAb 163,211, and 42 were provided by H.W. Kunz, 
PhD, University of Pittsburgh, Department of Pathol-
ogy, Pittsburgh, Pa. 
None 
None 
CsA 15 12-25 
CsA 25 12-25 
CsA 25 12-25 
FK-506 1 12-25 
FK-506 1.5 12-25 
FK-506 1.0 + 0.1 12-25 + 27-40 
The MAb 163, 211, and 42 were added as primary 
biotinylated antibodies at a 1:50 dilution and were in-
cubated for 60 minutes at 4° C. Cells were resuspended 
in fluorescein isothiocynate-conjugated avidin as a sec-
ondary marker and were analyzed on a flow cytometer 
(Epics Profile; Coulter Electronics, Hialeah, Fla.). 
Statistical analysis. Survival was calculated by the 
life-table method, with the mean survival time being 
derived from that time at which 50% of the animals were 
surviving. The follow-up in this study was 60 days. 
Comparisons of survival were analyzed with the Wilcox-
on's signed rank test with unequal variances. Two-
tailed p values <0.05 were considered statistically sig-
nificant. 
RESULTS 
Assessment of chimerism. Flow-cytometric analysis 
of peripheral blood lymphocytes showed reconstitution 
of the allogeneic BM recipients with more than 95% 
ACI cells in all tested animals (Fig. 1). 
Recovery from GVHD. Treatment groups are pre-
sented in Table II. Control animals not rescued with 
BM infusion after 1000 rad lethal total body irradiation 
died within 16 days (group 1). Animals receiving allo-
geneic BM + spleen cells after total body irradiation 
developed acute GVHD at a median day of 11, with a 
Volume 170 
Number 2 
FK 506 reverses acute GVHD in rats 359 
" 
LEW CELLS ACI CELLS j! 'I, 
, \ 
. , 
, , 
i i. 
~ 'I, 
i '\ 
a LEW , i 
.. aACI! \ 
'!IIIo...1 ' 
, . 
, \ 
1 \. i 
, I 
, " 
a ACI a LEW " '\ 
.L ~ .t¥+' . 
r II .. • ••••••• III.~ 
.t.III .... I •• t!..~.!!I'tllt .. tt .. t ..... !tt! ••••• I •• lltt.fl •••• ttt .......... ,II'f •••••• t:tII ••• , ................... ~1.1 •••••••• tl ... t ••••• I.t:t~!'i'., ••• ! •• ~.!!!.!!!!!t.!!!"'!!!.,t.!!!,'H~'========:::.=!!~ 
:v·t 
syn BMTx allo BMTx 11 ' '. 
:' " 
. , 
t~ 1 I \ . 
~: .~ 
a LEW aACI i \ 
.. ......, , 
, . 
. , 
.. \ 
I ~ , . , , 
I , , , 
i " 
aACI a LEW ;' \ 
, I': ~ 
............. te,.!!. _~.". .,tt ........ ·... """,' 
.,!., .. t! .. !..... II i ttU"'t'!'!~'!!!'!t'''i""!!.!",,,,, •• ,,, •••• ,,,,·''tiH''Htll'''''''''''II''m"'i .. m ................. .!!!.!! ....................... !!!, .... • ... r- .. ,f I I 1 
o 1 10 100 1000 1 10 100 1000 
(LOG) FLUORESCENCE INTENSITY 
Fig. 1. Single-color flow-cytometric assessment of cell phenotypes from Lewis (LEW) and ACI controls, a syn-
geneic reconstituted and a representative allogeneic BM recipient. Four weeks after BMTx, peripheral blood 
lymphocytes were tested for the presence of donor type ACI lymphoid cells with MAb 163 (anti-LEW) and MAb 
211 (anti-ACI). Animals receiving allogeneic BM repopulated with 95% donor type ACI cells. 
range of 8 to 12 days. All animals that did not receive 
immunosuppressive therapy (group 2) died within 26 
days with severe symptoms of GVHD. 
The 14-day course of immunosuppressive therapy 
was initiated on day 12 after BMTx after clinical and 
histologic GVHD were present. GsA given at 15 or 25 
mg/kg per day on days 12 to 25 (groups 3 and 4) was 
able to reverse GVHD in 42% and 55%, respectively 
(Table III). The remaining allogeneic BM recipients 
died either during therapy or failed to recover from 
GVHD. 
All animals receiving FK 506 at 1.0 or 1.5 mg/kg/ 
day, for the same 14-day period (groups 6 and 7), were 
rescued, with no death caused by GVHD (Table III). 
The animals treated with FK 506 recovered slightly 
earlier at 19 to 21 days (groups 6 and 7), compared to 
23 and 24 days in the GsA-treated animals (groups 3 
and 4). 
Recurrence of GVHD after cessation of immuno-
suppressive therapy. In all GsA-treated animals and in 
75% and 50% of animals (groups 6 and 7) receiving a 
14-day course of 1.0 and 1.5 mg/kg/day FK 506, 
respectively, GVHD eventually recurred after immu-
nosuppressive therapy was stopped (Table IV). Recur-
rence of GVHD in FK 506-treated animals was sub-
stantially delayed, when compared to the GsA-treated 
groups. Recurrence of GVHD was prevented in ani-
mals in group 8, which received low-dose treatment with 
FK 506 at 0.1 mg/kg/ day every other day up to 40 days, 
after the same 14-day induction treatment with 1.0 
mg/kg/day used in group 6. With this regimen, GVHD 
recurrence was always prevented during the study pe-
riod of 60 days. In all animals spared for 60 days, no 
matter in which group, GVHD recurred, except for 
three animals, which were treated with FK 506 (3/27) 
and survived without displaying GVHD for more than 
100 days. 
Treatment death in GsA-treated animals was higher 
than in animals receiving FK 506 (Fig. 2). Six of 12 
animals given GsA at 15 mg/kg/day and four of nine 
animals receiving GsA at 25 mg/kg/day died during 
therapy. No death was seen in the FK 506-treated 
~.----.-,.,- ~ --. -.,------------,------
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Table III. Recovery from GVHD 
Dose Recovery from GVHD 
Group Treatment (mg/kg) Days n % Yes/no Day * Survival (days) p valuef 
2 Untr BMTx 10 0 0/10 16, 18, 19, 19,20,25, 
26, 26, 26, 26 
3 CsA 15 12-25 12 42 5/12 23 14,14,14,17,22,22, NSt 
42, 42, 42, 42, 42, 42 
4 CsA 25 12-25 9 55 5/9 24 14,16,17,18,36,40, NSt 
40,41,41 
5 CsA 25 12-25 8 All >60 <0.009 
6 FK-506 12-25 8 100 8/8 21 48, 54, 54, 57, 57, >60, <0.01 
>60, >60 
7 FK-506 1.5 12-25 6 100 6/6 19 53, 53, >60, >60, >60, <0.03 
>60 
8 FK-506 1 +0.1 qod 12-25 + 27-40 8 100 8/8 21 All >60 <0.009 
Cjod, Every other da\", 
+\Vilcoxon signed rank tc~t for survival of treatment (groups 3 through 8) versus untreated BMTx (group 2). 
t'" Ol significant. p > {J.OS 
Table IV. Recurrence of GVHD after cessation of immunosuppresive therapy 
Recurrence of GVHD 
Group Treatment Dose (mg/kg) Days n % Yes/no Day * MST 
2 Untr BMTx 10 
3 CsA 15 12-25 12 100 5/5 28 32 
4 CsA 25 12-25 9 100 5/5 35 38 
6 FK-506 1 12-25 8 75 6/8 52 57 
7 FK-506 1.5 12-25 6 50 3/6 56 >60 
8 FK-S06 1 + 0.1 god 12-25 + 27 -40 8 0 0/8 >60 
,\/sr, Median sun'iva! time in days; qod, every other day. 
*l'vledian day of ret'Uffence. 
Table V. Histopathologic assessment of GVHD 
GVHD at days after BMTx 
Group Treatment Dose (mg/kg) Days n 12 25 45 
2 Untr BMTx 3 2+ 2+ * 
3 CsA 15 12-25 4 1-2+ 1+ * 
4 CsA 25 12-25 4 1-2+ 0-1+ * 
6 FK-506 1 12-25 4 1-2+ 0 0-1+ 
7 FK-506 1.5 12-25 4 1-2+ 0 0-1+ 
8 FK-506 1.0 + 0.1 god 12-25 + 27-40 4 1-2+ 0 0 
*q()", Every other day. Not available because all :lIlimals died because of GVHD. 
groups during the same time period. Prolongation of 
survival time was statistically significant for all FK 
506-treated groups, compared to untreated BM recip-
ients (Table III) and compared to both groups given 
GsA (versus group 4 [GsA 25 mg]; groups 6, p > 0.01; 
group 7, p > 0.03; group 8, p > 0.0001). The prolon-
gation of survival in the GsA-treated animals versus 
untreated controls was not significant (group 3,p > 0.41; 
group 4, p > 0.15). 
To assess if toxicity of GsA therapy was a reason for 
the high mortality rate, one group of animals (group 5) 
was given syngeneic BM and treated with a dose of 25 
mg/kg/day on days 12 to 25. In this group no death was 
seen up to 60 days after treatment, and all animals were 
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Volume 710 
Number 2 
100 
80 
60 
40 
20 
r-
-
o 
o 
+ 
• 
FK 1.0 
FK 1.0+C 
FK 1.5 
lI1tr 8M 
l~l ~~Vl 
'P I I 
'V-o J 
1000 TBI Lr'ltr 8M 
,°1 
I 
v 
10 20 30 
o 
o 
FK 506 reverses acute GVHD in rats 361 
CsA 15 
1000 TBI 
1-
+ 
+ 
o 
1 
CsA 25 CsA 15 
~ ~ 
CsA 25 
CsA 25sy~ 
I 
~I 
1 
MJ 
if' 
FK 1. O+C 
t::. 
l FK t 1.5 
+-+ 
if' 
FK 1.0 
I 
40 50 60 
DAYS POST RECONSTITUTION 
Fig. 2. Survival from GVHD of allogeneic BM recipients treated with GsA or FK 506 at various doses_ Animals 
received either GsA at 25 mg (GsA 25) or 15 mg (GsA 15) /kg/day or FK 506 at 1.0 mg (FK 1.0) or 1.5 mg 
(FK 1.5) /kg/day on day 12 to 25 after BMTx. In one group, FK 506 treatment was continued after the in-
duction period of 1.0 mg/kg/day on days 12 to 25 with 0.1 mg/kg/every other day to day 40 after BMTx (FK 
1.0 + G). One group that served as a GsA-toxicity control received a syngeneic BMTx and GsA at 25 mg/kg/day 
on day 12 to 25. Also included are untreated BM recipients (untT BM) and irradiation controls (1000 TBI). 
in excellent health without any indication of drug tox-
icity. 
Histologic evidence. All animals displayed histo-
logic evidence of GVHD on day 12 when therapy was 
started (Table V). After 2 weeks of treatment, histologic 
signs of GVHD persisted in CsA-treated animals with 
vacuolar degeneration and lymphocytic infiltration of 
the epidermis (Fig. 3). In contrast the FK 506-treated 
animals had no histologic signs of GVHD in biopsies 
taken on day 25. At 45 days after BMTx no animals 
from the untreated group or the CsA-treated group were 
alive. At this time point 20 days after cessation of the 
14-day course of immunosuppression, both FK 506-
treated groups (groups 6 and 7) displayed evidence of 
GVHD. Recurrence of GVHD was not seen in the skin 
of animals receiving continuous low-dose treatment of 
FK 506 every other day (Table V). 
DISCUSSION 
We have shown that a 14-day course of FK 506 can 
reliably reverse established GVHD, something not 
achieved with CsA. The high mortality rate during CsA 
treatment could be attributed to death from GVHD, 
drug toxicity, or a combination of both. CsA toxicity as 
the primary factor was ruled out in syngeneic BM re-
cipients (group 5), which had no deaths when treated 
with 25 mg/kg/day. Thus the better results with FK 
506 were attributable to the superior immunosuppres-
sion with this agent. In vitro studies have shown FK 506 
to be about 50 to 100 times more potent than CsA.9 To 
achieve an effectiveness of CsA comparable to that of FK 
506, doses in the toxic range would be required.21 
However, in the dose used of 25 mg/kg/day, a CsA ef-
fect could be seen, a finding consistent with clinical ob-
servations that CsA is effective for the treatment of hu-
man GVHD.3 Our experimental results are in contrast 
to an earlier negative report in which the onset and se-
verity of GVHD in rats was not altered when oral CsA 
was started 7 days after BMTx.22 The difference in 
these results may have been due to the dosage of CsA and 
the oral route chosen in the earlier study. Absorption of 
the orally administered drug could be unreliable in such 
experiments because of damage of the small bowel from 
total body irradiation and GVHD. This damage was 
362 Markus et al. Surgery 
August 1991 
Fig. 3. Ear biopsies from Lewis recipients of allogeneic BM at 12, 25, and 45 days after BMTx. GVHD was 
present on day 12 (A) before treatment was sta rted. N ote disrupt ion of the basal membrane, lymphocy tic infil-
tration of the epidermis, a nd vacuolar degeneration and necrosis. No GVHD was found at the end of the treat-
ment period (B) in anima ls receiving FK 506 at 1.0 mg/kg/ day. In contrast, esA at 25 mg/ kg/day was not able 
to reverse his tologic signs of GVHD (C). At 45 days after BMTx, GVHD recurred histologically in most rats 
treated with FK 506 at 1.0 mg/kg/ day (D). In contrast continuous low-dose treatment with FK 506 at 0.1 mg/ 
kg/ day on days 27 to 40 after the induction period (E) prevented the recurrence of GVHD. (Hematoxylin-eosin; 
original magnifica tion X500.) 
seen histopathologically in all of our control animals. In 
all of our experiments with either CsA or FK 506, the 
drugs were given intramuscularly. 
The mechanism of both immunosuppressive agents 
has been studied extensively in in vitro experiments. 
Although CsA and FK 506 bind to different cytosolic 
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receptors,23,24 both have been shown to suppress the 
expression of the interleukin-2 receptor and the release 
of interleukin-28, 16 and to interfere with the activation 
ofT cells.16 Why the drugs are effective when given late 
is speculative. Conceivably the appearance of suppres-
sor cells under delayed therapy could be responsible for 
reversing signs of GVHD. Spleen cells in CsA-treated 
BM recipients have been reported to suppress mixed 
lymphocyte reactions between donor and recipient-type 
cells. 19 Alternatively they might interfere with the acti-
vation and expansion of T cells. Whatever the explana-
tion, clearly both FK 506 and CsA can be therapeuti-
cally useful long after immunologic activation starts, 
One of the striking qualities of FK 506 is its ability to 
reverse episodes of graft rejection in humans. This was 
reported in the first trials with FK 506 for the rescue of 
patients experiencing acute and chronic rejection of solid 
organ grafts, despite previous treatment with CsA, cor-
ticosteroids, and OKT3. 13, 15 
Although the ability to treat GVHD in recipients of 
BM is an important achievement, prevention of this 
process may have an even higher priority. We have de-
scribed elsewhere that GVHD can be avoided with FK 
506 in the same rat model herein reported, with greater 
ease and reliability than with CsA.25 In addition, these 
findings have application beyond BMTx. The ability to 
prevent or control GVHD should change the approach 
and expectations with the transplantation of solid 
organs, such as the intestine, which are rich in lymphoid 
tissue and therefore capable of mounting GVHD. 
We thank Jo Harnaha, BS, Gennaro Selvaggi, and Judy 
Wargo, MS, for technical assistance and Dr. H.W. Kunz for 
his expert advice and assistance in flow cytometry. 
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DISCUSSION 
Dr. Andreas G. Tzakis (Pittsburgh, Pa.). We have fol-
lowed Dr. Markus' work with great interest because we have 
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clinical evidence that FK 506 is eff eClive in the treatment of 
GVHD. We have treated three children at the Children's 
Hospital in Pittsburgh with FK 506. All did not respond to 
first-line and second-line conventional treatment. Two of these 
children had been treated for 8 months, and the third child had 
been treated for 1 Y2 months. They all had gastrointestinal, 
skin, and liver involvement; the third patient had alveoli tis 
obliterans as well. The gastrointestinal, skin, and hepatic in-
volvement all resolved within 3 weeks to 3 months after ini-
tiation of the treatment. The lung involvement did not 
improve. 
Dr. Roberta E. Sonnino (Cleveland, Ohio). You showed us 
the result of skin biopsies. Did you look at the other organs that 
are usually affected by GVHD, and if so, whal was the extent 
of involvement? Were you able to reverse it in all organs? 
Also, you obviously continued to use FK 506 at a mainte-
nance low dose. Did you carry the studies out any further af-
ter FK 506 was discontinued to see whether you could induce 
tolerance off immunosuppression as we have found you can do 
at times with cyclosporine? With bowel transplantations, for 
instance, rats will develop tolerance to cyclosporine. Did you 
find a similar situation with FK 506 or did you have to leave 
them on a low dose permanently? 
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Dr. Markus (closing). Responding to the last question, we 
are looking at the prevention of GVHD by FK 506 in a sep-
arate study in which we examine all organs. We know that the 
GVHD will induce effects in other organs. We did reverse the 
GVHD also in other organs. The liver is a poor organ to fol-
low GVHD in rats because it is not the primary target as it 
is in humans. A better organ to follow in rats probably is the 
small intestine. 
Concerning the second question, we continued the low-dose 
treatment further in a couple of animals for up to 60 or 80 days. 
The rate of tolerance induction was not higher than what we 
saw in our shorter term treatments. Overall, we have had 
about 5% to 10% of animals that were free of GVHD and that 
displayed some sort of tolerance. This incidence was not ob-
viously influenced by the duration of FK 506 treatment. 
Dr. Tzakis, this is of course acute GVHD in our rats. The 
patients who have been treated had chronic GVHD. We are 
just developing a model to treat the chronic GVHD in rats. We 
are delighted to hear the positive reports in clinical bone mar-
row transplantation. 
